|1.||Mignot, Emmanuel: 79 articles (12/2015 - 01/2002)|
|2.||Nishino, Seiji: 51 articles (11/2014 - 03/2002)|
|3.||Sakurai, Takeshi: 47 articles (06/2015 - 12/2002)|
|4.||Kanbayashi, Takashi: 39 articles (06/2015 - 03/2002)|
|5.||Dauvilliers, Yves: 36 articles (07/2015 - 01/2003)|
|6.||Plazzi, Giuseppe: 34 articles (10/2015 - 12/2008)|
|7.||Mignot, E: 33 articles (10/2012 - 01/2000)|
|8.||Yanagisawa, Masashi: 32 articles (10/2015 - 06/2002)|
|9.||Overeem, Sebastiaan: 31 articles (10/2015 - 10/2002)|
|10.||Lin, Ling: 29 articles (10/2015 - 06/2002)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
03/01/2011 - "Genetic studies suggest orexin receptor antagonists could be therapeutic for insomnia and other disorders with disruptions of sleep and wake. "
11/01/2014 - "Despite its limitations, suvorexant's market entry offers a truly novel treatment for insomnia, paving the way for follow-up compounds and opening therapeutic avenues in other disorders for orexin receptor modulating compounds. "
05/01/2014 - "Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. "
05/01/2014 - "Orexin receptor antagonists: a new treatment for insomnia?"
12/04/2012 - "We evaluated suvorexant, an orexin receptor antagonist, for treating patients with primary insomnia in a randomized, double-blind, placebo-controlled, 2-period (4 weeks per period) crossover polysomnography study. "
11/01/2010 - "These results show that prolonged wakefulness, better sleep quality, lower sleep drive and greater orexin signaling may confer protection against obesity."
12/22/2000 - "Furthermore, the suppression of nocturnal feeding and food intake stimulated by an overnight fast supports other evidence that orexin-A is involved in the regulation of natural feeding and suggests that orexin-1 receptor antagonists could be useful in the treatment of obesity."
01/01/2014 - "Discussion of these questions will provide a summary of the current state of knowledge regarding hypothalamic orexin regulation of physical activity during aging and provide a platform on which to develop improved clinical outcomes in age-associated obesity and metabolic syndromes. "
03/01/2015 - "We first discuss animal models used in studies of obesity and sleep, including loss of function using transgenic or viral-mediated approaches, gain of function models using exogenous delivery of orexin receptor agonist, and naturally-occurring models in which orexin responsiveness varies by individual. "
12/01/2013 - "However, despite early findings in feeding and appetite control, orexin receptor antagonists have not produced the anticipated effects in models of increased food intake or obesity in rodents, nor have they shown marked effects on weight in the existing clinical trials. "
|3.||Disorders of Excessive Somnolence (Hypersomnia)
07/01/2008 - "Dysfunction of the hypocretin system has been reported in MS case reports with attacks of hypothalamic lesions, undetectable cerebrospinal fluid (CSF) hcrt-1 and hypersomnia, but not found during remission in small samples. "
08/01/2005 - "Hypersomnia and a decrease of the CNS orexin A improved after corticosteroid therapy. "
11/01/2006 - "To study DQB1*0602 status and hypocretin-1 levels in the cerebrospinal fluid (CSF) in a cohort of patients with hypersomnolence and to test International Classification of Sleep Disorders-2 (ICSD-2) criteria for hypersomnia of central origin. "
01/01/2014 - "After recovering from the stupor, the patient exhibited the symptoms of hypersomnia with low orexin level in the CSF. "
01/01/2013 - "Inclusion of patients with other central hypersomnias without hypocretin deficiency will provide answer to the major question of the role of the hypocretin system in reward-based behaviors and emotional processing in humans."
11/01/2003 - "It is very useful to measure CSF orexin for the diagnosis of early onset narcolepsy."
01/01/2013 - "Although studies on hypocretin-deficient mice have shown that hypocretin plays an essential role in reward-seeking, depression-like behavior and addiction, results in human narcolepsy remained subject to debate. "
01/01/2013 - "The current study determined the effects of orexin gene transfer into the dorsolateral pontine neurons in the orexin knockout (KO) mice model of narcolepsy. "
11/01/2012 - "Animal models and human studies concordantly show that the disturbed hypocretin system is the probable cause of narcolepsy. "
10/01/2012 - "Decreased cerebrospinal fluid orexin levels and sleep studies confirmed the diagnosis of narcolepsy due to medical condition. "
01/01/2013 - "Orexin gene transfer into the dorsolateral pons significantly decreased cataplexy and modestly improved wake maintenance compared to the orexin KO mice that did not receive rAAV. "
10/01/2008 - "During the 4-day life-span of the vector the incidence of cataplexy declined by 60%, and the levels of rapid eye movement sleep during the second half of the night were similar to levels in wild-type mice, indicating that narcoleptic sleep-wake behavior in orexin KO mice can be improved by targeted gene transfer."
09/23/2011 - "The present study investigated the effects of attractive and aversive odor stimuli, i.e., urine samples of coyote and female mice, on narcoleptic episodes (cataplexy, sleep attacks) in orexin-deficient mice. "
07/01/2006 - "Recent studies have shown reduced hypocretin-1 levels in the cerebrospinal fluid (CSF) of narcoleptic patients with cataplexy. "
08/19/2015 - "These findings confirm recent data obtained in the hypocretin knock-out mice and suggest that the absence of hypothalamic hypocretin control on mesolimbic reward centers is crucial in determining cataplexy induced by emotions. "
|2.||((2R)- 2- ((1S)- 6,7- dimethoxy- 1- (2- (4- trifluoromethylphenyl)- ethyl)- 3,4- dihydro- 1H- isoquinolin- 2- yl)- N- methyl- 2- phenylacetamide)
|3.||Messenger RNA (mRNA)
|7.||Asp(5)- oxytocin (OXA)
|8.||Biological Markers (Surrogate Marker)
|10.||Morphine (MS Contin)
|2.||Continuous Positive Airway Pressure